Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05907096 · ClinicalTrials.gov registry record · Phase 2
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
A Phase 2 study of Delayed Graft Function, sponsored by argenx.
- Active
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT05907096 is a Phase 2 study of Delayed Graft Function that is active but no longer recruiting, run by argenx. The registered enrollment target is 103 participants, below the 357-participant average among 6 other Delayed Graft Function trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05907096, a Phase 2 study of Delayed Graft Function, is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function. The study consists of 2 parts: part A comprises the main study period, and part B comprises the long-term observational follow-up period. During part A, after the screening period, eligible participants will be randomized to receive either ARGX-117 or placebo, entering the treatment and evaluation period (duration of up to 52 weeks). After the treatment period, participants will enter a follow-up period of up to 12 weeks. The total study duration varies from approximately 64 weeks up to 5 years post-transplant depending on whether a participant enrols in part B of the study.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL ARGX-117
Study Locations (20)
Other
- Royal Adelaide Hospital - Adelaide
- Monash Health - Monash Medical Centre - Clayton
- Princess Alexandra Hospital - Woolloongabba
- Tirol Kliniken - A.o. Landeskrankenhaus Innsbruck - Innsbruck
- Allgemeines Krankenhaus der Stadt Wien (AKH Wien) - Vienna
- Universitair Ziekenhuis Leuven - Leuven
- Centro Hospitalar e Universitario de Coimbra - Coimbra
- Hospital Geral de Fortaleza - Fortaleza
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vicente Scherer - Porto Alegre
- Hospital de Base - São Jose Do Rio Preto
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP) - São Paulo
- Hôpital Maisonneuve-Rosemont - Centre de recherche - Montreal
New York
- Erie County Medical Center - Buffalo
- Columbia University - New York
California
- Cedars-Sinai Medical Center - Los Angeles
Florida
- Tampa General Hospital - Tampa
Illinois
- University of Illinois (UI) Health - Outpatient Care Center - Chicago
New Jersey
- Cooperman Barnabas Medical Center - Livingston
Ohio
- The Ohio State University - Columbus
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2024-02-17 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05907096
The ClinicalTrials.gov registry entry for NCT05907096 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 6 other Delayed Graft Function trials with a reported enrollment target (71% lower). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delayed Graft Function appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05907096 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT05907096 about?
NCT05907096 is a clinical study titled "ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function". The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function. The study consists of 2 parts: part A comprises the main study period, and part B comprises the long-term observational ...
What is the current status of trial NCT05907096?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2024-02-17. Estimated completion is 2026-07-31.
What conditions does trial NCT05907096 study?
This clinical trial studies the following conditions: Delayed Graft Function.
What interventions are being tested in trial NCT05907096?
The interventions under investigation include: Placebo (OTHER), ARGX-117 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05907096?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05907096 being conducted?
This trial has 20 study locations across California, Florida, Illinois, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delayed Graft Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
RECRUITING · Phase 1
-
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
RECRUITING · Phase 3
-
Deceased Organ Donor Interventions to Protect Kidney Graft Function
COMPLETED · NA
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
COMPLETED · Phase 4
-
Envarsus in Delayed Graft Function (E-DGF)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.